Endovascular infections caused by Candida species, including endocarditis, prosthetic graft infections, and septic thrombophlebitis, are being increasingly recognized (4, 11, 13, 14, 17) . This increase relates to the common use of indwelling intravascular catheters for antibiotic, chemotherapy, or hyperalimentation administrations, as well as prosthetic valve and graft placements for cardiovascular indications, highlighting the propensity of Candida strains to adhere to such prosthetic materials (10) . Although Candida endovascular infections are difficult to eradicate with antifungal therapy alone (3, 11) , such treatment is an integral part of the combined medical-surgical approaches to these infections (16) .
To date, amphotericin B has been the preeminent antifungal agent for the treatment of invasive Candida infections, since this agent is active in vitro against most Candida strains and is fungicidal (6) . However, enthusiasm for the therapeutic use of this drug has been counterbalanced by its well-known acute and chronic toxicities, such as fevers, rigors, hypotension, and renal insufficiency (7) . Fluconazole is a new antifungal triazole with a limited toxicity profile, favorable human pharmocokinetics, and activity in vitro against the majority of Candida species (2, 12) .
We previously showed, using the rabbit model of Candida albicans endocarditis (19) , that both fluconazole and amphotericin B were effective in the treatment of an established valvular infection, although amphotericin B was more rapidly fungicidal in vivo. The current study was designed to compare the therapeutic efficacies of amphotericin B and fluconazole in the rabbit model of Candida endocarditis caused by the non-C. albicans species C. parapsilosis and C. tropicalis. This study was prompted by the recent emergence of these latter species in a variety of human infections, especially endocarditis (C. parapsilosis [10] ) and fungemia in immunocompromised hosts (C. tropicalis [8, 18] (10) . The organisms were pelleted by centrifugation, washed twice, and resuspended in 0.85% NaCl. After resonication, the organisms were counted and adjusted with a hemocytometer to achieve the final appropriate infecting fungal inoculum (ca. 2 x 107 CFU/ml).
Confirmation of the infecting inoculum was obtained by making standard serial dilution plate counts on yeast nitrogen base agar (Difco).
Fluconazole was supplied as a powder (Diflucan; Pfizer Inc., Groton, Conn.). The drug was dissolved in 10% (vol! vol) Cremophor EL (Sigma Chemical Co., St. Louis, Mo.) at a final concentration of 12.5 mg/ml for intraperitoneal (i.p.) administrations. We previously showed that equivalent serum fluconazole levels are achieved when this agent is administered to rabbits by either the intravenous (i.v.) or the i.p. route (19) . Amphotericin B (Fungizone; E. R. Squibb & Sons, Princeton, N.J.) was purchased and prepared in accordance with the manufacturer's directions for i.v. administrations.
The antimicrobial susceptibilities of C. parapsilosis and C. tropicalis to amphotericin B and fluconazole were determined by Michael Rinaldi (Fungus Testing Laboratory, University of Texas Health Sciences Center, San Antonio) using the broth macrodilution method and synthetic amino acid medium for fungi. The 24-h in vitro antifungal susceptibilities of the two species were determined in parallel at final inocula of ca. 104 and 106 CFU/ml to encompass the range of fungal densities ordinarily achieved within experimental vegetations in the rabbit model (19) .
We used the same therapeutic antifungal strategies as those previously published (19) carditis. However, with this organism, as opposed to C. parapsilosis, the rates of clearance of intravegetation fungi were significantly more rapid with amphotericin B than with fluconazole (Table 3) . For example, after 11 days of therapy, only amphotericin B had significantly reduced intravegetation fungal densities, compared with those in untreated controls, while both agents were equally effective in this regard after 21 days of therapy. The current study was prompted by the recent emergence of non-C. albicans Candida species as important causes of fungemia and disseminated infections in both immunocompetent (6, 8) and immunocompromised (1, 9, 18) hosts. Several interesting observations were forthcoming from this study. We found that both amphotericin B and fluconazole were very efficacious agents in the treatment of established endocarditis caused by the non-C. albicans Candida species studied. For C. parapsilosis, both amphotericin B and fluconazole were equally effective and rapidly fungicidal in vivo, with significant reductions in intravegetation fungal densities after 11 days of therapy. However, against established C. tropicalis endocarditis, amphotericin B was more rapidly fungicidal in vivo after 11 days of therapy, although both regimens were equally effective when therapy was extended to 21 days. This latter experience with C. tropicalis parallels our previous observations in comparing amphotericin B and fluconazole for the treatment of experimental C. albicans endocarditis (19) . Thus, our previous and current studies both confirm that fluconazole and amphotericin B are effective in treating established endovascular infections with various Candida species, although the treatment response is generally slower with fluconazole. The reason(s) for the more rapid in vivo killing of C. parapsilosis than of C. tropicalis by fluconazole in this endocarditis model is undoubtedly complex and may relate in part to the lower minimal fungicidal concentration for C. parapsilosis (10 ,ug/ml) than for C. tropicalis (>80 ,ug/ml) and the lower in vivo rate of growth of C. parapsilosis, yielding substantially lower final intravegetation fungal densities in untreated C. parapsilosis controls than in untreated C. tropicalis controls.
The dose of fluconazole used in this study (100 mg/kg i.p.) yielded peak levels in serum (approximately 100 p,g/ml [19] ) at least 40 times the MICs for both Candida species. The pharmacokinetics of fluconazole at standard clinical dosages in humans (50 to 100 mg/day) appear to be linear, with achievable levels in serum ranging from 2 to 6 ,ug/ml (15) . On the basis of these data, it is possible that the current high-dose fluconazole strategies now being studied for invasive human mycoses (1,200 to 1,800 mg/day) may well result in peak levels in serum approaching those achieved in our animal model.
